USFDA11 Dec 2025, 05:51 pm
Indoco Remedies Ltd Receives EIR from USFDA for API Manufacturing Facility at Patalganga
AI Summary
Indoco Remedies Limited has announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Active Pharmaceutical Ingredients (API) manufacturing facility located at Patalganga. This comes after a successful inspection of the facility from 15th to 19th September, 2025. The EIR reinforces Indoco's commitment to upholding the highest standards of quality and compliance, delivering trusted healthcare solutions to patients worldwide.
Key Highlights
- Indoco Remedies Ltd receives EIR from USFDA for its API manufacturing facility at Patalganga
- The EIR follows a successful USFDA inspection of the facility from 15th to 19th September, 2025
- This reinforces Indoco's commitment to quality and compliance in delivering healthcare solutions
- Indoco's API manufacturing facility at Patalganga is now approved by the USFDA